AI Drug Discovery for Pharma and Biotech

Drug discovery

2

drugs

With orphan designations

Overview

Pleural empyema, a collection of pus in the pleural space, typically arises from complications of pneumonia, thoracic procedures, or trauma. It progresses through exudative, fibrinopurulent, and organized stages, causing symptoms like chest pain, fever, and respiratory compromise [1][6][11]. Diagnosis involves imaging and pleural fluid analysis, while treatment combines antibiotics, drainage (thoracentesis/chest tubes), intrapleural fibrinolytics, and surgery (VATS/decortication) for advanced cases [3][8][13]. Mortality ranges from 6.9% to 16.1%, with rising incidence linked to aging populations and influenza [4][12][17].

Population

  • Incidence rising globally, particularly in elderly males and those with comorbidities (diabetes, COPD, asthma) [4][9][17].

  • Seasonal correlation with influenza peaks, especially in children and young adults [14][19].

  • Higher risk in patients with poor dental hygiene, immunosuppression, or thoracic trauma [5][7][11].

Burden

  • Median hospitalization 12-17 days, with 15% requiring surgical intervention [4][12].

  • Mortality 6.9-16.1%, rising to 50% in hospital-acquired cases [7][12][17].

  • Annual U.S./U.K. healthcare costs exceed $500 million, with 65,000+ cases yearly [2][7][12].

Therapies

  1. Early-stage: Antibiotics + image-guided thoracentesis or small-bore chest tubes [1][13].

  2. Loculated effusions: Intrapleural fibrinolytic therapy (e.g., alteplase/DNase) to enhance drainage [8][13].

  3. Advanced cases: VATS or open decortication for lung re-expansion, achieving 83-98% success rates [3][17][12].

Categories: rare respiratory diseases

Research Papers

1,870 drug discovery papers about Pleural empyema, with 2 first-in-class and 1 next-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

1,870 drug discovery papers about Pleural empyema, with 2 first-in-class and 1 next-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-28 | Evidence-Based Guideline on Prioritized Issues for the Management of Empyema Thoracis in Children.

The lack of clarity in the management of pediatric empyema thoracis necessitates evidence-based guidance. To develop an evidence-based guideline on high-priority issues in pediatric empyema management (laboratory investigations, antibiotic therapy, intrapleural fibrinolytic therapy, surgical intervention, and follow-up). The guideline was developed using contemporary methodology, viz. establishing a Steering Group; setting up an Evidence-Based Guideline Development Group (EBGDG); collating formal declarations of interest and managing conflicts; identifying and prioritizing questions; evidence synthesis; critical appraisal using GRADE methodology; translating evidence to recommendation statements; external peer review; and finalization of the guideline document. The dominant pathogen causing empyema in Indian children is Staphylococcus aureus, followed by Streptococcus pneumoniae. Therefore, the empirical antibiotics (pending culture reports) should preferably be the combination of Cloxacillin and Ceftriaxone (conditional recommendation, very low certainty of evidence). On the issue of intrapleural fibrinolytic therapy (IPFT) vs. no IPFT as the initial modality, pediatricians could use either option (in addition to oxygen, appropriate antibiotics, and effective pleural pus drainage) as the limited evidence did not show significant differences for critical outcomes (conditional recommendation, very low certainty of evidence). However, IPFT is recommended as the initial modality of therapy compared to Video-Assisted Thoracoscopic Surgery (VATS), on account of comparable efficacy, moderate savings, enhanced equity, stakeholder acceptability, and feasibility in diverse settings (conditional recommendation, very low certainty of evidence). The EBGDG does not recommend any particular intrapleural fibrinolytic agent over another due to a lack of comparative evidence (conditional recommendation, no evidence). The superiority of early initiation of IPFT (i.e. as the initial management, or at presentation), compared to late(r) instillation is not established in the absence of any evidence (conditional recommendation, no evidence). No recommendation can be made regarding the use of initial intrapleural fibrinolytic therapy (IPFT) (i.e., at or close to confirmation of empyema) versus IPFT after failure of intercostal chest drain (ICD) alone because of the absence of evidence (conditional recommendation, no evidence). Antibiotic therapy for ≤4 weeks is not suggested in preference to therapy for >4 weeks, despite the absence of direct evidence, owing to greater clinical experience with the latter, as well as its acceptability and feasibility (conditional recommendation, no evidence). Routine use of microbiologic molecular methods in preference to conventional culture techniques is not suggested, on account of greater specificity and lower cost of culture (conditional recommendation, very low certainty of evidence). Routine use of CT scan in preference to ultrasonography is not suggested for the management of children with empyema (conditional recommendation, very low evidence certainty). No clinical, radiological, microbiological, biomarker, or pleural fluid characteristics, either individually or in combination, were identified as predictors of failure of medical management (conditional recommendation, very low certainty of evidence). For each evidence-based recommendation, detailed justification, implementation considerations, and research priorities are outlined. This evidence-based guideline, developed using robust methodology, offers practical guidance for the management of empyema thoracis in children. This is expected to enhance the quality and standardization of care.

Open article ↗



2026-09-14 | Metagenomic Next-Generation Sequencing for the Diagnosis of Trichomonas Vaginalis-Associated Empyema: a Case Report and Literature Review.

This report describes a rare case of empyema caused by Trichomonas vaginalis co-infected with Streptococcus agalactiae and Streptococcus pyogenes, aiming to explore the role of T. vaginalis in the development of empyema, its diagnostic methods, and treatment strategies. The patient was a 46-year-old male who presented with cough, sputum production, and shortness of breath. The diagnosis was made using chest CT, routine pleural fluid analysis, bacterial culture, and metagenomic next-generation sequencing (mNGS). Pleural fluid examination revealed numerous motile Trichomonas organisms, and bacterial culture identified Streptococcus agalactiae and Streptococcus pyogenes as the pathogens. Fur-ther mNGS confirmed these bacteria as the causative agents, with 39 Trichomonas sequences detected, including 32 sequences specific to T. vaginalis. The patient received combination antimicrobial therapy and underwent chest tube drainage and thoracoscopic empyema debridement. Post-treatment, the patient's condition significantly improved. A literature review revealed that while Trichomonas tenax is a common pathogen in empyema, T. vaginalis is an extremely rare cause. T. vaginalis infection may be associated with bacterial co-infections, immunosuppression, or poor hygiene. This case is the first report of T. vaginalis induced empyema, expanding the understanding of Trichomonas infections. Although such infections are rare, they should be considered in high-risk patients. Further studies are needed to investigate the infection pathways of T. vaginalis and its mechanisms of bacterial synergy in disease pathogenesis to improve clinical diagnosis and treatment strategies.

Open article ↗



2026-09-01 | State of the ART: practical evaluation and management of pleural infection.

This review synthesizes recent evidence and provides a stepwise approach to management, emphasizing timely recognition of treatment failure, appropriate escalation of therapy, and individualized decision-making to optimize clinical outcomes. The cornerstone of pleural infection management is appropriate antibiotic therapy and effective pleural drainage. Most infections are polymicrobial, with anaerobic organisms predominating. Image-guided chest tube drainage remains the standard initial intervention. Early recognition of inadequate drainage or persistent pleural infection-related sepsis through close clinical, biochemical, and radiographic assessment is essential to facilitate timely escalation of care. Intrapleural enzyme therapy (IET) reduces the need for surgery, and emerging evidence suggests that lower-dose tissue plasminogen activator (tPA) regimens may preserve efficacy. Current evidence supports a sequential management strategy in which IET precedes surgery, with early thoracic surgical consultation and prompt recognition of IET failure to avoid delays that may increase surgical morbidity. Successful management of pleural infection depends on early source control, vigilant assessment of treatment response, and timely escalation of care. A structured, stepwise approach that integrates antibiotics and effective pleural drainage, early use of IET when indicated, and prompt surgical consultation for nonresponders offers the best opportunity to improve outcomes while minimizing morbidity.

Open article ↗



2026-08-24 | Clinical case of acute purulent empyema caused by Elizabethkingia anopheles

Acute purulent pleural empyema is a severe post-surgical complication, typically caused by common pathogens. However, rare opportunistic bacteria such as Elizabethkingia anophelis can lead to severe infections that are difficult to treat due to broad antibiotic resistance. We analyzed clinical data of a 69-year-old male patient with pleural empyema following lung lobectomy. Staged interventions were performed (endobronchial valve occlusion, thoracoscopic pleural sanitation, open thoracostomy) alongside advanced microbiological examinations (pathogen identification by MALDI-ToF MS and susceptibility testing according to EUCAST criteria). Standard empirical antimicrobial therapy (meropenem, metronidazole) was ineffective. E. anophelis, resistant to most antibiotics, was isolated from the pleural exudate. Early accurate identification of the rare pathogen E. anophelis and a multimodal treatment strategy (adequate pleural drainage with combined antibiotic therapy) led to a successful outcome, highlighting the importance of timely diagnosis and a multidisciplinary approach. Keywords: pleural empyema, Elizabethkingia anopheles, antibiotic resistance, thoracic surgery, opportunistic infection.

Open article ↗



2026-08-19 | Culture-Negative Pyogenic Liver Abscess Presenting as Lung Abscess and Empyema Through Transdiaphragmatic Spread.

A woman in her 40s presented with progressive dyspnoea and cough, preceded by anorexia and significant weight loss. Initial chest radiography showed apparent elevation of the right hemidiaphragm with right lower zone opacification, raising concern for thoracic or intra-abdominal malignancy. Laboratory investigations revealed severe normocytic anaemia, leucocytosis, hypoalbuminaemia and elevated alkaline phosphatase. Contrast-enhanced CT demonstrated a large subcapsular right hepatic abscess with contiguous transdiaphragmatic extension into the right lower thorax, complicated by lung abscess and pleural empyema. Blood and liver abscess cultures were negative; the liver aspirate was obtained after 7 days of antimicrobial therapy. She was treated with antimicrobial therapy and image-guided liver abscess drainage, achieving sustained clinical and biochemical recovery, with ultrasonographic resolution of the hepatic collection. This case highlights the importance of considering a subdiaphragmatic source in patients presenting with lung abscess or empyema adjacent to the right hemidiaphragm.

Open article ↗



antibodies
2025-08-18 | The role of interleukin-6 signalling in pleural infection: observational and genetic analyses.

Pleural infection is associated with marked local and systemic inflammation leading to significant morbidity. It may be possible to therapeutically augment this response and interleukin-6 is a key signalling cascade in inflammatory pathologies. We performed a prospective observational study recruiting patients with pleural effusions secondary to infection and measured interleukin-6 in matched pleural fluid and serum (n = 76). We subsequently performed a large-scale, two sample Mendelian Randomisation study (1601 cases and 830,709 controls), using genetic variation at IL6R to proxy the effect of interleukin-6 inhibition on pleural infection and overcome confounding inherent in observational analyses. Pleural interleukin-6 levels in infection were 5000-fold higher than matched serum levels (median 72,752 pg/ml vs. 15 pg/ml). Pleural interleukin-6 predicted systemic inflammation (neutrophil count, C- reactive protein), correlated with clinical markers of disease severity (effusion size, pH, glucose), and was strongly associated with length of hospital stay. In Mendelian randomisation analyses, interleukin-6 inhibition was predicted to have a large protective effect on the incidence of infection (OR 0.23; 95% CI 0.14-0.39 per standard deviation decrease in C- reactive protein). The effect size was larger than that seen in COVID-19 and coronary artery disease, where interleukin-6 inhibition has been successful in trials. Multiple lines of evidence suggest pleural interleukin-6 drives pathology in pleural infection. Targeting interleukin-6 may hold promise and should be considered in randomised trials. This study has been funded by the National Institutes of Health and Care Research Bristol Biomedical Research Centre.

Open article ↗



2024-12-20 | IMMUNOLOGICAL DISORDERS IN PLEURAL EMPYEMA AND THE POSSIBILITY OF THEIR CORRECTION

Abstract. Problems in the treatment of acute pleural empyema are caused by a number of objective and subjective reasons, in particular, such as the widespread spread of antibiotic-resistant microflora and allergization of the population. Literature data indicate the need to improve immunostimulating therapy in patients with pleural empyema. A study of the long-term results of all types of treatment for this pathology shows that they do not give 100% success. The presented data indicate the need to improve immunostimulating therapy in patients with pleural empyema.

Open article ↗



2020-10-05 | Precision Targeting of the Plasminogen Activator Inhibitor-1 Mechanism Increases Efficacy of Fibrinolytic Therapy in Empyema

Abstract Plasminogen activator inhibitor-1 (PAI-1) is an endogenous irreversible inhibitor of tissue-type (tPA) and urokinase (uPA) plasminogen activators. PAI-1-targeted fibrinolytic therapy (PAI-1-TFT) is designed to decrease the therapeutic dose of tPA and uPA to attenuate the risk of bleeding and other complications. The docking site peptide (DSP) is a part of the PAI-1 reactive center loop, which interacts with plasminogen activators, thus affecting the PAI-1 mechanism. We used DSP for PAI-1-TFT in two rabbit models: chemically-induced pleural injury and Streptococcus pneumoniae induced empyema. PAI-1-TFT with DSP combined with single chain uPA or tPA resulted in an up to 8-fold decrease in the minimal effective therapeutic dose of plasminogen activator and induced no bleeding. An increase in the level of PAI-1 in infectious pleural injury, when compared to chemically-induced injury, coincided with an increase in the minimal effective dose of plasminogen activator and DSP. PAI-1 is a valid molecular target in S. pneumoniae empyema model in rabbits, which closely recapitulates key characteristics of empyema in humans. Low dose PAI-1-TFT is a novel precise interventional strategy that may improve fibrinolytic therapy of empyema in clinical practice.

Open article ↗



2015-07-07 | Salmonella Enteritidis Empyema Preceding the Diagnosis of Non-Hodgkin’s Lymphoma and Subsequent Contralateral Chylothorax Treated with Radiolabelled Rituximab

Salmonella infection is common, but pleural involvement has rarely been reported.Only seven cases of Salmonella enteritidis pleural empyema have been reported; all had an associated preexisting underlying immunosuppresion or malignancy.We report the case of an apparently healthy man who developed S. enteritidis empyema.On further follow-up and surveillance, he eventually presented with non-Hodgkin's lymphoma and a contralateral recurrent chylothorax.The latter was successfully controlled with radiolabeled rituximab, which has never been described for the above purpose in literature before.

Open article ↗



2015-05-22 | Campylobacter fetus bacteremia with purulent pleurisy in a young adult with primary hypogammaglobulinemia.

A 24-year-old man presented with fever and pleural effusion predominantly containing lymphocytes. Cultures of the pleural effusion and blood revealed Campylobacter fetus, and laboratory studies showed a low serum level of immunoglobulin. The patient was diagnosed with C. fetus pleuritis, bacteremia and primary hypogammaglobulinemia, and subsequent treatment with meropenem and immunoglobulin improved his condition. Although the underlying cause of the primary hypogammaglobulinemia remains unclear, the patient's status improved under immunoglobulin replacement therapy. C. fetus pleuritis is a rare infectious disease usually observed in immunocompromised hosts. We herein describe the first report of C. fetus pleuritis in a young adult with primary hypogammaglobulinemia.

Open article ↗



cell therapies
2026-08-12 | Role of omental flaps in thoracic surgery complications: a narrative review.

The greater omentum is a highly vascularized and immunologically active organ with recognized regenerative and antimicrobial properties. Its application in pleural space complications has gained renewed interest with the expansion of minimally invasive harvesting techniques. This review summarizes the current literature regarding the role of omental flaps in the management of post-lobectomy complications. This narrative review was conducted using a comprehensive search of MEDLINE (Via PubMed), Scopus, and Cochrane Central Register of Controlled Trials from database inception through February 2026 using the search terms "Omental flap", "pleural space", and "bronchopleural fistula", "post-lobectomy complications", "entrapped lung" and "empyema". Peer-reviewed articles in English and Spanish were included. Data were extracted and synthesized narratively, focusing on indications, techniques, outcomes, advantages, and limitations. Omental flaps are most used for bronchopleural fistula (BPF), empyema, mediastinitis, and prosthetic graft coverage. Rich vascular and lymphatic networks of the omentum enhance infection control and tissue healing, particularly in contaminated or high-risk fields. The size and pliability of the omentum allow effective obliteration of complex pleural dead space problems and durable coverage of critical structures. Reported flap survival rates range from 80-100% in small case series. Omental flaps represent a versatile and biologically advantageous option for pleural space complications. Although current evidence is limited and largely observational, reported outcomes are promising, warranting further prospective investigation.

Open article ↗



2026-06-04 | Surgical management of recurrent MRSA empyema with eloesser flap in a complex thoracic patient: lessons from endobronchial valve failure.

Endobronchial valves (EBVs) have emerged as a minimally invasive option for managing bronchopleural fistula (BPF), with reported efficacy rates of approximately 70-75%. However, their long-term performance in the setting of chronic infection remains poorly characterized, and documentation of specific failure mechanisms is limited. A 74-year-old man with recurrent methicillin-resistant Staphylococcus aureus (MRSA) empyema following right lower lobectomy presented with treatment failure 14 months after Zephyr EBV placement. During Eloesser flap creation, both valves were found displaced from the bronchial stump, with one completely dislodged into the pleural space. The bronchial stump showed evidence of erosion from chronic infection. The patient demonstrated clinical improvement following the Eloesser procedure, with negative cultures at three-month follow-up. This case provides direct intraoperative visualization of EBV displacement in chronic empyema, suggesting that ongoing infection, tissue destruction, and mechanical forces may compromise valve stability over time. The finding supports consideration of patient selection criteria for EBV therapy and demonstrates the continued role of open drainage procedures when minimally invasive approaches fail.

Open article ↗



2026-04-04 | Single-stage open window thoracostomy with simultaneous muscle flap transposition and early negative pressure wound therapy for chronic empyema: a propensity score- and machine learning-based study.

BACKGROUND: To compare the clinical efficacy of a single-stage surgical approach combining open window thoracostomy, muscle flap transposition, and early negative pressure wound therapy (NPWT) with that of conventional staged management for chronic empyema. METHODS: This retrospective, single-center cohort included 45 patients with chronic empyema (single-stage, n = 7; conventional, n = 38) who were treated from 2009 to 2024. The primary endpoint was the cavity reduction ratio measured via three-dimensional computed tomography (3D CT). To minimize selection bias, we applied propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). We prespecified the average treatment effect on the treated (ATT) as the primary estimand, whereas the average treatment effect (ATE) was considered exploratory because treatment assignment was strongly related to bronchopleural fistula (all single-stage patients had BPF) and overlap was limited. The follow-up intervals were linearly normalized to adjust for time-dependent variability. Machine learning models were used as complementary predictive analyses to identify predictors of cavity reduction. RESULTS: After PSM (n = 5 per group), the single-stage group had significantly greater cavity reduction than the conventional group did (90% [89–94%] vs. 37% [32–43%], p = 0.008). The IPTW analysis demonstrated significant treatment effects: 0.38 (95% CI: 0.17–0.59, p = 0.005) for the ATT and 0.63 (95% CI: 0.12–1.14, p = 0.03) for the ATE (exploratory). Machine learning models consistently identified the treatment approach and time-related variables as important predictors of cavity reduction. CONCLUSIONS: Compared with conventional management, the single-stage approach was associated with significantly greater empyema cavity reduction and was feasible even in patients with bronchopleural fistulas. Causal interpretation is most defensible for the ATT, whereas generalization to the full population (ATE) should be considered exploratory due to limited overlap. Despite the small sample size, the consistent findings across diverse analytical frameworks support the single-stage strategy as a promising approach that warrants prospective multicenter validation and clearer criteria for patient selection.

Open article ↗



2026-02-12 | An alternative method of closure of open window thoracostomy: a two-staged approach.

Refractory empyema poses significant treatment challenges, but open window thoracostomy (OWT) remains an effective solution, facilitating infection control and promoting recovery. However, after the resolution of infection, patients often face complications due to the open pleural cavity and residual pleural space. The closure of open window thoracostomies is particularly difficult, especially in the presence of large residual spaces and bronchopleural fistulas (BPFs). This case series examines six patients who underwent OWT for empyema of various etiologies, employing a two-stage approach: intra-thoracic vacuum therapy followed by closure of the residual pleural space with a pedicled muscle flap. The outcomes demonstrate the feasibility and effectiveness of this technique in addressing complex OWT closure challenges and improving patient outcomes.

Open article ↗



2025-12-31 | Erythrocyte photomodification in discrete plasmapheresis as a detoxification method in acute pleural empyema

Background. Acute pleural empyema is a severe disease accompanied by high systemic intoxication, metabolic disturbances, and purulent septic complications. Conventional therapy – antibiotics, pleural drainage, and infusions – may be insufficient due to accumulation of toxins and disruption of homeostasis. While extracorporeal methods such as plasmapheresis appear promising, classic approaches are limited by substantial losses of plasma proteins and immune components. Photomodification of erythrocytes may enhance detoxification and stimulate tissue repair processes. Aim. To assess the clinical efficacy, safety, and impact on tissue repair of three variants of detoxifying hemocorrection: Therapeutic Plasma Exchange (TPE), TPE with Partial Photomodification of Erythrocytes (TPE-PPE), and Small Volume TPE with Full Photomodification of Erythrocytes (SV-TPE-FPE) in patients with acute pleural empyema. Materials and Methods. A total of 105 patients with acute nonspecific pleural empyema treated at the Institute of General and Emergency Surgery (2008–2024) were enrolled. Patients were stratified into four groups: control (standard therapy), TPE, TPE-PPE, and SV-TPE-FPE. Apheresis procedures were performed every other day. Efficacy was monitored via clinical parameters (body temperature, duration of fever, severity of condition), complications, and morphological changes. Statistical analysis was carried out using variation statistics and Student's t-test, with Bonferroni correction for multiple comparisons. The study was carried out as a private initiative of the authors, without grant support or state registration of the topic. Research Ethics. The study was conducted in accordance with the principles of the World Medical Association Declaration of Helsinki (1964–2024) and approved by the Ethics Committee of the Educational and Scientific Medical Institute of National Technical University "Kharkiv Polytechnic Institute" (Protocol No.2 dated October 13, 2023). Written informed consent for the use of clinical data in scientific research was obtained from all patients, with adherence to the principles of confidentiality and voluntary participation. Results. The SV-TPE-FPE group demonstrated the best clinical dynamics: maximal body temperature decreased to 37.1°C, and the fever period was shortest (mean ≈ 18 days). The complication rate in this group was significantly lower than in other groups: fewer purulent septic complications and a reduced need for surgical interventions. No deaths were recorded in the SV-TPE-FPE group. Morphologically, there was the largest proportion of spontaneous scarring of pleural cavities in this group, suggesting activation of reparative processes. Conclusions. Small volume TPE with full photomodification of erythrocytes (SV-TPE-FPE) appears to be a promising method for treating acute pleural empyema, combining effective detoxification with activation of repair and reduced complication rates with no fatal outcomes in the studied sample. These findings support incorporating photomodified erythrocytes into comprehensive therapy, but further multicenter randomized studies are required to validate these results. Keywords: surgery, purulent diseases of the pleura, laboratory diagnostic.

Open article ↗



proteins
2026-09-24 | Impact of urokinase shortage on empyema management and clinical outcomes in Japan.

Urokinase is an important fibrinolytic therapy for empyema. In February 2022, a nationwide shortage occurred, but its impact remains unclear. We conducted a retrospective cohort study using a nationwide Japanese administrative database. Adults with empyema who underwent pleural drainage or surgery from January 2020 to December 2023 were identified. Treatment changes were evaluated using interrupted time-series (ITS) analysis and visualized with an alluvial plot. Clinical outcomes were evaluated using multivariable logistic regression. The primary outcome was in-hospital mortality, and the secondary outcome was prolonged hospitalization (≥60 days). Among 9104 patients, urokinase use declined from 27.1% to 9.2%, whereas surgery increased from 18.9% to 23.0% after February 2022. ITS analysis demonstrated significant post-restriction slope changes in urokinase use (odds ratio [OR] = 0.87, 95% confidence interval [CI] = 0.86-0.88) and surgery (OR = 1.03, 95% CI = 1.01-1.04). The alluvial plot showed reduced urokinase use and increased surgical and conservative management. In-hospital mortality was 13.8% before and 14.5% after the shortage, and the shortage period was not associated with increased in-hospital mortality (adjusted OR: 1.05, 95% CI: 0.92-1.20). No clear increase in prolonged hospitalization was observed. The urokinase shortage substantially altered empyema management, although no clear worsening of short-term clinical outcomes was detected.

Open article ↗



2026-07-20 | Intrapleural Fibrinolytic Therapy in the Management of Pediatric Pleural Empyema: A Narrative Review

Background: Pediatric pleural empyema is a major complication of community-acquired pneumonia and remains associated with substantial morbidity despite advances in vaccination, antimicrobial therapy, and supportive care. Intrapleural fibrinolytic therapy has become an important minimally invasive treatment for complicated parapneumonic effusions and empyema, but uncertainty persists regarding the optimal fibrinolytic agent, treatment protocols, patient selection, and indications for surgical intervention. Methods: A narrative review of the literature was conducted to summarize current evidence on the use of intrapleural fibrinolytic therapy in pediatric pleural empyema. Experimental studies, randomized controlled trials, observational studies, systematic reviews, meta-analyses, and international clinical practice guidelines were critically reviewed. Particular attention was paid to the biological rationale for fibrinolysis, pharmacological characteristics of available agents, comparative effectiveness with video-assisted thoracoscopic surgery (VATS), practical treatment protocols, safety, and future research priorities. Results: Intrapleural fibrinolysis effectively improves pleural drainage by lysing fibrin septations during the fibrinopurulent stage of empyema and is associated with shorter hospitalization compared with chest-tube drainage alone. Urokinase remains the fibrinolytic agent supported by the highest-quality pediatric randomized evidence, whereas alteplase has demonstrated favorable outcomes in observational studies and randomized comparisons with VATS. Current evidence indicates comparable clinical outcomes between fibrinolysis and primary VATS in appropriately selected children, although fibrinolysis is generally associated with lower treatment costs and avoidance of surgery in most patients. Conventional-dose fibrinolytic therapy has an acceptable safety profile, with clinically significant bleeding reported only rarely. Current pediatric evidence does not support the routine addition of DNase to tissue plasminogen activator. Conclusion: Intrapleural fibrinolytic therapy represents a safe, effective, and minimally invasive first-line treatment for most children with complicated parapneumonic effusions and pleural empyema requiring drainage. Management should be individualized within a multidisciplinary framework, integrating timely diagnosis, image-guided pleural drainage, appropriate antimicrobial therapy, and selective surgical intervention. Future multicenter studies are needed to optimize fibrinolytic protocols, validate predictive biomarkers, and further standardize clinical management.

Open article ↗



2026-06-19 | Intrapleural Fibrinolytics use in Children with Pleural Empyema: Safe and Effective.

We assessed the number of children with pleural empyema in which video assisted thoracoscopy (VATS) could be avoided in a center where standard therapy is drainage using a chest drain with/without intrapleural fibrinolytics. We included all children referred for chest drainage of a pleural effusion to RadboudUMC between 01-2022 and 04-2023. Children were referred in case of pneumonia with respiratory distress and suspected pleural effusion on the chest X-ray or an effusion size >20mm in the chest ultrasound, indicating the need for chest drainage or VATS. We analyzed symptoms, test results, and treatment. Thirty-three children aged 0-16 years were referred for treatment of pleural effusion. Most children presented with fever, cough and dyspnea (72%). Four children presented with abdominal pain (13%), which led to 2 appendectomies prior to referral. In 11 (33%) children an invasive group A streptococcus was cultured from the pleural fluid. All patients were treated with antibiotics. One patient received VATS primarily. 27 (84%) patients received a chest drain and four patients continued conservative treatment. 14 (52%) of the 27 children with a chest drain were treated with intrapleural fibrinolytics (alteplase or urokinase) because of persistent pleural effusion on ultrasound despite chest drainage. No side effects were observed. Two patients received VATS secondary to chest drainage without receiving prior intrapleural fibrinolytics. Intrapleural fibrinolytic treatment appeared safe and could avoid VATS in children with poor drainage and is therefore a useful minimal invasive treatment in children with pleural empyema.

Open article ↗



2026-06-18 | The LTI-01-2001 phase 2a trial of intrapleural LTI-01 in patients with infected, non-draining pleural effusions.

Single chain urokinase (LTI-01) intrapleural enzymatic therapy (IET) was safe and promising in a phase 1 clinical trial to overcome failed drainage in patients with pleural infection. The LTI-01-2001 phase 2a trial was a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study in hospitalized subjects with infected, non-draining pleural effusions. LTI-01, in doses of 400,000, 800,000 or 1,200,000 Units, or placebo was administered intrapleurally once daily for up to 3 days. The primary efficacy endpoint was incidence of treatment failure within 7 days of starting study medication. Treatment failure was defined as requiring alternative pleural therapy irrespective of subsequent treatment. Pleural opacification was a secondary endpoint and was assessed by CT imaging of the change in opacified area expressed as a percentage of the ipsilateral hemithorax (relative change) or absolute change in pleural opacification volume expressed in liters. 40/43 enrolled patients received LTI-01 or placebo due to constraints of the COVID-19 pandemic. There was no significant difference in incidence of treatment failure between the LTI-01 and placebo groups (OR 1.04, 95% CI 0.24,4.44, P = 0.96) while two predetermined sensitivity analyses demonstrated trends of improved efficacy in the 400,000 U group (P = 0.052 and 0.147). The absolute (Liters; L) and relative change from baseline in opacity volume were - 0.28 L (p=0.035) and - 55.8% (P = 0.064) versus placebo in the 800,000 U group, with significant reduction in absolute opacification found in the 400,000 and all LTI-01-treated groups combined (P < 0.03, respectively). There were no safety signals of concern, nor were there any episodes of intrapleural or pulmonary bleeding in LTI-01-treated patients. No statistically significant difference in the incidence of treatment failure was seen, potentially related to low recruitment. Trends towards efficacy were observed in predetermined sensitivity analyses at the 400,000 U dose of intrapleural LTI-01. Pleural opacification appeared most improved by the 800,000 U intrapleural LTI-01. A larger phase 2b trial is required to confirm these results or determine the efficacy of LTI-01 in patients with organizing, nondraining, infected pleural effusions. ClinicalTrials.gov NCT04159831. Registration date: November 12, 2019.

Open article ↗



2026-05-25 | Extended Intrapleural Tissue Plasminogen Activator (tPA)-Dornase Alfa (DNase) Therapy Beyond the Standard Multicenter Intrapleural Sepsis Trial 2 (MIST-2) Regimen in a High-Risk Patient With Complex Empyema: A Case Report.

Pleural infection, including complicated parapneumonic effusion and empyema, remains a major management challenge, especially in patients who are poor surgical candidates. The Multicenter Intrapleural Sepsis Trial 2 (MIST-2) supports a six-dose regimen of intrapleural tissue plasminogen activator (tPA) plus dornase alfa (DNase), but the optimal duration of therapy in patients with persistent loculations remains uncertain. We describe a 62-year-old man with morbid obesity, New York Heart Association class III diastolic heart failure, and poorly controlled type 2 diabetes mellitus who presented with a complex, loculated left-sided empyema caused by Gemella sanguinis and Escherichia coli. Because of prohibitive operative risk, he was not considered a candidate for video-assisted thoracoscopic surgery. After incomplete improvement following the standard six-dose regimen, characterized by persistent fever, persistently elevated inflammatory markers, and residual loculations on repeat imaging, intrapleural therapy was extended for an additional six doses, for a total of 12 doses over six days. The patient had marked clinical and radiographic improvement, complete lung re-expansion, and no bleeding complications. This case suggests that, in carefully selected high-risk patients with persistent loculated empyema and no surgical option, extended intrapleural tPA-DNase therapy may be a feasible individualized strategy beyond the fixed MIST-2 protocol.

Open article ↗



small molecules
2026-09-28 | Evidence-Based Guideline on Prioritized Issues for the Management of Empyema Thoracis in Children.

The lack of clarity in the management of pediatric empyema thoracis necessitates evidence-based guidance. To develop an evidence-based guideline on high-priority issues in pediatric empyema management (laboratory investigations, antibiotic therapy, intrapleural fibrinolytic therapy, surgical intervention, and follow-up). The guideline was developed using contemporary methodology, viz. establishing a Steering Group; setting up an Evidence-Based Guideline Development Group (EBGDG); collating formal declarations of interest and managing conflicts; identifying and prioritizing questions; evidence synthesis; critical appraisal using GRADE methodology; translating evidence to recommendation statements; external peer review; and finalization of the guideline document. The dominant pathogen causing empyema in Indian children is Staphylococcus aureus, followed by Streptococcus pneumoniae. Therefore, the empirical antibiotics (pending culture reports) should preferably be the combination of Cloxacillin and Ceftriaxone (conditional recommendation, very low certainty of evidence). On the issue of intrapleural fibrinolytic therapy (IPFT) vs. no IPFT as the initial modality, pediatricians could use either option (in addition to oxygen, appropriate antibiotics, and effective pleural pus drainage) as the limited evidence did not show significant differences for critical outcomes (conditional recommendation, very low certainty of evidence). However, IPFT is recommended as the initial modality of therapy compared to Video-Assisted Thoracoscopic Surgery (VATS), on account of comparable efficacy, moderate savings, enhanced equity, stakeholder acceptability, and feasibility in diverse settings (conditional recommendation, very low certainty of evidence). The EBGDG does not recommend any particular intrapleural fibrinolytic agent over another due to a lack of comparative evidence (conditional recommendation, no evidence). The superiority of early initiation of IPFT (i.e. as the initial management, or at presentation), compared to late(r) instillation is not established in the absence of any evidence (conditional recommendation, no evidence). No recommendation can be made regarding the use of initial intrapleural fibrinolytic therapy (IPFT) (i.e., at or close to confirmation of empyema) versus IPFT after failure of intercostal chest drain (ICD) alone because of the absence of evidence (conditional recommendation, no evidence). Antibiotic therapy for ≤4 weeks is not suggested in preference to therapy for >4 weeks, despite the absence of direct evidence, owing to greater clinical experience with the latter, as well as its acceptability and feasibility (conditional recommendation, no evidence). Routine use of microbiologic molecular methods in preference to conventional culture techniques is not suggested, on account of greater specificity and lower cost of culture (conditional recommendation, very low certainty of evidence). Routine use of CT scan in preference to ultrasonography is not suggested for the management of children with empyema (conditional recommendation, very low evidence certainty). No clinical, radiological, microbiological, biomarker, or pleural fluid characteristics, either individually or in combination, were identified as predictors of failure of medical management (conditional recommendation, very low certainty of evidence). For each evidence-based recommendation, detailed justification, implementation considerations, and research priorities are outlined. This evidence-based guideline, developed using robust methodology, offers practical guidance for the management of empyema thoracis in children. This is expected to enhance the quality and standardization of care.

Open article ↗



2026-09-14 | Metagenomic Next-Generation Sequencing for the Diagnosis of Trichomonas Vaginalis-Associated Empyema: a Case Report and Literature Review.

This report describes a rare case of empyema caused by Trichomonas vaginalis co-infected with Streptococcus agalactiae and Streptococcus pyogenes, aiming to explore the role of T. vaginalis in the development of empyema, its diagnostic methods, and treatment strategies. The patient was a 46-year-old male who presented with cough, sputum production, and shortness of breath. The diagnosis was made using chest CT, routine pleural fluid analysis, bacterial culture, and metagenomic next-generation sequencing (mNGS). Pleural fluid examination revealed numerous motile Trichomonas organisms, and bacterial culture identified Streptococcus agalactiae and Streptococcus pyogenes as the pathogens. Fur-ther mNGS confirmed these bacteria as the causative agents, with 39 Trichomonas sequences detected, including 32 sequences specific to T. vaginalis. The patient received combination antimicrobial therapy and underwent chest tube drainage and thoracoscopic empyema debridement. Post-treatment, the patient's condition significantly improved. A literature review revealed that while Trichomonas tenax is a common pathogen in empyema, T. vaginalis is an extremely rare cause. T. vaginalis infection may be associated with bacterial co-infections, immunosuppression, or poor hygiene. This case is the first report of T. vaginalis induced empyema, expanding the understanding of Trichomonas infections. Although such infections are rare, they should be considered in high-risk patients. Further studies are needed to investigate the infection pathways of T. vaginalis and its mechanisms of bacterial synergy in disease pathogenesis to improve clinical diagnosis and treatment strategies.

Open article ↗



2026-09-01 | State of the ART: practical evaluation and management of pleural infection.

This review synthesizes recent evidence and provides a stepwise approach to management, emphasizing timely recognition of treatment failure, appropriate escalation of therapy, and individualized decision-making to optimize clinical outcomes. The cornerstone of pleural infection management is appropriate antibiotic therapy and effective pleural drainage. Most infections are polymicrobial, with anaerobic organisms predominating. Image-guided chest tube drainage remains the standard initial intervention. Early recognition of inadequate drainage or persistent pleural infection-related sepsis through close clinical, biochemical, and radiographic assessment is essential to facilitate timely escalation of care. Intrapleural enzyme therapy (IET) reduces the need for surgery, and emerging evidence suggests that lower-dose tissue plasminogen activator (tPA) regimens may preserve efficacy. Current evidence supports a sequential management strategy in which IET precedes surgery, with early thoracic surgical consultation and prompt recognition of IET failure to avoid delays that may increase surgical morbidity. Successful management of pleural infection depends on early source control, vigilant assessment of treatment response, and timely escalation of care. A structured, stepwise approach that integrates antibiotics and effective pleural drainage, early use of IET when indicated, and prompt surgical consultation for nonresponders offers the best opportunity to improve outcomes while minimizing morbidity.

Open article ↗



2026-08-24 | Clinical case of acute purulent empyema caused by Elizabethkingia anopheles

Acute purulent pleural empyema is a severe post-surgical complication, typically caused by common pathogens. However, rare opportunistic bacteria such as Elizabethkingia anophelis can lead to severe infections that are difficult to treat due to broad antibiotic resistance. We analyzed clinical data of a 69-year-old male patient with pleural empyema following lung lobectomy. Staged interventions were performed (endobronchial valve occlusion, thoracoscopic pleural sanitation, open thoracostomy) alongside advanced microbiological examinations (pathogen identification by MALDI-ToF MS and susceptibility testing according to EUCAST criteria). Standard empirical antimicrobial therapy (meropenem, metronidazole) was ineffective. E. anophelis, resistant to most antibiotics, was isolated from the pleural exudate. Early accurate identification of the rare pathogen E. anophelis and a multimodal treatment strategy (adequate pleural drainage with combined antibiotic therapy) led to a successful outcome, highlighting the importance of timely diagnosis and a multidisciplinary approach. Keywords: pleural empyema, Elizabethkingia anopheles, antibiotic resistance, thoracic surgery, opportunistic infection.

Open article ↗



2026-08-19 | Culture-Negative Pyogenic Liver Abscess Presenting as Lung Abscess and Empyema Through Transdiaphragmatic Spread.

A woman in her 40s presented with progressive dyspnoea and cough, preceded by anorexia and significant weight loss. Initial chest radiography showed apparent elevation of the right hemidiaphragm with right lower zone opacification, raising concern for thoracic or intra-abdominal malignancy. Laboratory investigations revealed severe normocytic anaemia, leucocytosis, hypoalbuminaemia and elevated alkaline phosphatase. Contrast-enhanced CT demonstrated a large subcapsular right hepatic abscess with contiguous transdiaphragmatic extension into the right lower thorax, complicated by lung abscess and pleural empyema. Blood and liver abscess cultures were negative; the liver aspirate was obtained after 7 days of antimicrobial therapy. She was treated with antimicrobial therapy and image-guided liver abscess drainage, achieving sustained clinical and biochemical recovery, with ultrasonographic resolution of the hepatic collection. This case highlights the importance of considering a subdiaphragmatic source in patients presenting with lung abscess or empyema adjacent to the right hemidiaphragm.

Open article ↗



antibodies
2025-08-18 | The role of interleukin-6 signalling in pleural infection: observational and genetic analyses.

Pleural infection is associated with marked local and systemic inflammation leading to significant morbidity. It may be possible to therapeutically augment this response and interleukin-6 is a key signalling cascade in inflammatory pathologies. We performed a prospective observational study recruiting patients with pleural effusions secondary to infection and measured interleukin-6 in matched pleural fluid and serum (n = 76). We subsequently performed a large-scale, two sample Mendelian Randomisation study (1601 cases and 830,709 controls), using genetic variation at IL6R to proxy the effect of interleukin-6 inhibition on pleural infection and overcome confounding inherent in observational analyses. Pleural interleukin-6 levels in infection were 5000-fold higher than matched serum levels (median 72,752 pg/ml vs. 15 pg/ml). Pleural interleukin-6 predicted systemic inflammation (neutrophil count, C- reactive protein), correlated with clinical markers of disease severity (effusion size, pH, glucose), and was strongly associated with length of hospital stay. In Mendelian randomisation analyses, interleukin-6 inhibition was predicted to have a large protective effect on the incidence of infection (OR 0.23; 95% CI 0.14-0.39 per standard deviation decrease in C- reactive protein). The effect size was larger than that seen in COVID-19 and coronary artery disease, where interleukin-6 inhibition has been successful in trials. Multiple lines of evidence suggest pleural interleukin-6 drives pathology in pleural infection. Targeting interleukin-6 may hold promise and should be considered in randomised trials. This study has been funded by the National Institutes of Health and Care Research Bristol Biomedical Research Centre.

Open article ↗



2024-12-20 | IMMUNOLOGICAL DISORDERS IN PLEURAL EMPYEMA AND THE POSSIBILITY OF THEIR CORRECTION

Abstract. Problems in the treatment of acute pleural empyema are caused by a number of objective and subjective reasons, in particular, such as the widespread spread of antibiotic-resistant microflora and allergization of the population. Literature data indicate the need to improve immunostimulating therapy in patients with pleural empyema. A study of the long-term results of all types of treatment for this pathology shows that they do not give 100% success. The presented data indicate the need to improve immunostimulating therapy in patients with pleural empyema.

Open article ↗



2020-10-05 | Precision Targeting of the Plasminogen Activator Inhibitor-1 Mechanism Increases Efficacy of Fibrinolytic Therapy in Empyema

Abstract Plasminogen activator inhibitor-1 (PAI-1) is an endogenous irreversible inhibitor of tissue-type (tPA) and urokinase (uPA) plasminogen activators. PAI-1-targeted fibrinolytic therapy (PAI-1-TFT) is designed to decrease the therapeutic dose of tPA and uPA to attenuate the risk of bleeding and other complications. The docking site peptide (DSP) is a part of the PAI-1 reactive center loop, which interacts with plasminogen activators, thus affecting the PAI-1 mechanism. We used DSP for PAI-1-TFT in two rabbit models: chemically-induced pleural injury and Streptococcus pneumoniae induced empyema. PAI-1-TFT with DSP combined with single chain uPA or tPA resulted in an up to 8-fold decrease in the minimal effective therapeutic dose of plasminogen activator and induced no bleeding. An increase in the level of PAI-1 in infectious pleural injury, when compared to chemically-induced injury, coincided with an increase in the minimal effective dose of plasminogen activator and DSP. PAI-1 is a valid molecular target in S. pneumoniae empyema model in rabbits, which closely recapitulates key characteristics of empyema in humans. Low dose PAI-1-TFT is a novel precise interventional strategy that may improve fibrinolytic therapy of empyema in clinical practice.

Open article ↗



2015-07-07 | Salmonella Enteritidis Empyema Preceding the Diagnosis of Non-Hodgkin’s Lymphoma and Subsequent Contralateral Chylothorax Treated with Radiolabelled Rituximab

Salmonella infection is common, but pleural involvement has rarely been reported.Only seven cases of Salmonella enteritidis pleural empyema have been reported; all had an associated preexisting underlying immunosuppresion or malignancy.We report the case of an apparently healthy man who developed S. enteritidis empyema.On further follow-up and surveillance, he eventually presented with non-Hodgkin's lymphoma and a contralateral recurrent chylothorax.The latter was successfully controlled with radiolabeled rituximab, which has never been described for the above purpose in literature before.

Open article ↗



2015-05-22 | Campylobacter fetus bacteremia with purulent pleurisy in a young adult with primary hypogammaglobulinemia.

A 24-year-old man presented with fever and pleural effusion predominantly containing lymphocytes. Cultures of the pleural effusion and blood revealed Campylobacter fetus, and laboratory studies showed a low serum level of immunoglobulin. The patient was diagnosed with C. fetus pleuritis, bacteremia and primary hypogammaglobulinemia, and subsequent treatment with meropenem and immunoglobulin improved his condition. Although the underlying cause of the primary hypogammaglobulinemia remains unclear, the patient's status improved under immunoglobulin replacement therapy. C. fetus pleuritis is a rare infectious disease usually observed in immunocompromised hosts. We herein describe the first report of C. fetus pleuritis in a young adult with primary hypogammaglobulinemia.

Open article ↗



cell therapies
2026-08-12 | Role of omental flaps in thoracic surgery complications: a narrative review.

The greater omentum is a highly vascularized and immunologically active organ with recognized regenerative and antimicrobial properties. Its application in pleural space complications has gained renewed interest with the expansion of minimally invasive harvesting techniques. This review summarizes the current literature regarding the role of omental flaps in the management of post-lobectomy complications. This narrative review was conducted using a comprehensive search of MEDLINE (Via PubMed), Scopus, and Cochrane Central Register of Controlled Trials from database inception through February 2026 using the search terms "Omental flap", "pleural space", and "bronchopleural fistula", "post-lobectomy complications", "entrapped lung" and "empyema". Peer-reviewed articles in English and Spanish were included. Data were extracted and synthesized narratively, focusing on indications, techniques, outcomes, advantages, and limitations. Omental flaps are most used for bronchopleural fistula (BPF), empyema, mediastinitis, and prosthetic graft coverage. Rich vascular and lymphatic networks of the omentum enhance infection control and tissue healing, particularly in contaminated or high-risk fields. The size and pliability of the omentum allow effective obliteration of complex pleural dead space problems and durable coverage of critical structures. Reported flap survival rates range from 80-100% in small case series. Omental flaps represent a versatile and biologically advantageous option for pleural space complications. Although current evidence is limited and largely observational, reported outcomes are promising, warranting further prospective investigation.

Open article ↗



2026-06-04 | Surgical management of recurrent MRSA empyema with eloesser flap in a complex thoracic patient: lessons from endobronchial valve failure.

Endobronchial valves (EBVs) have emerged as a minimally invasive option for managing bronchopleural fistula (BPF), with reported efficacy rates of approximately 70-75%. However, their long-term performance in the setting of chronic infection remains poorly characterized, and documentation of specific failure mechanisms is limited. A 74-year-old man with recurrent methicillin-resistant Staphylococcus aureus (MRSA) empyema following right lower lobectomy presented with treatment failure 14 months after Zephyr EBV placement. During Eloesser flap creation, both valves were found displaced from the bronchial stump, with one completely dislodged into the pleural space. The bronchial stump showed evidence of erosion from chronic infection. The patient demonstrated clinical improvement following the Eloesser procedure, with negative cultures at three-month follow-up. This case provides direct intraoperative visualization of EBV displacement in chronic empyema, suggesting that ongoing infection, tissue destruction, and mechanical forces may compromise valve stability over time. The finding supports consideration of patient selection criteria for EBV therapy and demonstrates the continued role of open drainage procedures when minimally invasive approaches fail.

Open article ↗



2026-04-04 | Single-stage open window thoracostomy with simultaneous muscle flap transposition and early negative pressure wound therapy for chronic empyema: a propensity score- and machine learning-based study.

BACKGROUND: To compare the clinical efficacy of a single-stage surgical approach combining open window thoracostomy, muscle flap transposition, and early negative pressure wound therapy (NPWT) with that of conventional staged management for chronic empyema. METHODS: This retrospective, single-center cohort included 45 patients with chronic empyema (single-stage, n = 7; conventional, n = 38) who were treated from 2009 to 2024. The primary endpoint was the cavity reduction ratio measured via three-dimensional computed tomography (3D CT). To minimize selection bias, we applied propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). We prespecified the average treatment effect on the treated (ATT) as the primary estimand, whereas the average treatment effect (ATE) was considered exploratory because treatment assignment was strongly related to bronchopleural fistula (all single-stage patients had BPF) and overlap was limited. The follow-up intervals were linearly normalized to adjust for time-dependent variability. Machine learning models were used as complementary predictive analyses to identify predictors of cavity reduction. RESULTS: After PSM (n = 5 per group), the single-stage group had significantly greater cavity reduction than the conventional group did (90% [89–94%] vs. 37% [32–43%], p = 0.008). The IPTW analysis demonstrated significant treatment effects: 0.38 (95% CI: 0.17–0.59, p = 0.005) for the ATT and 0.63 (95% CI: 0.12–1.14, p = 0.03) for the ATE (exploratory). Machine learning models consistently identified the treatment approach and time-related variables as important predictors of cavity reduction. CONCLUSIONS: Compared with conventional management, the single-stage approach was associated with significantly greater empyema cavity reduction and was feasible even in patients with bronchopleural fistulas. Causal interpretation is most defensible for the ATT, whereas generalization to the full population (ATE) should be considered exploratory due to limited overlap. Despite the small sample size, the consistent findings across diverse analytical frameworks support the single-stage strategy as a promising approach that warrants prospective multicenter validation and clearer criteria for patient selection.

Open article ↗



2026-02-12 | An alternative method of closure of open window thoracostomy: a two-staged approach.

Refractory empyema poses significant treatment challenges, but open window thoracostomy (OWT) remains an effective solution, facilitating infection control and promoting recovery. However, after the resolution of infection, patients often face complications due to the open pleural cavity and residual pleural space. The closure of open window thoracostomies is particularly difficult, especially in the presence of large residual spaces and bronchopleural fistulas (BPFs). This case series examines six patients who underwent OWT for empyema of various etiologies, employing a two-stage approach: intra-thoracic vacuum therapy followed by closure of the residual pleural space with a pedicled muscle flap. The outcomes demonstrate the feasibility and effectiveness of this technique in addressing complex OWT closure challenges and improving patient outcomes.

Open article ↗



2025-12-31 | Erythrocyte photomodification in discrete plasmapheresis as a detoxification method in acute pleural empyema

Background. Acute pleural empyema is a severe disease accompanied by high systemic intoxication, metabolic disturbances, and purulent septic complications. Conventional therapy – antibiotics, pleural drainage, and infusions – may be insufficient due to accumulation of toxins and disruption of homeostasis. While extracorporeal methods such as plasmapheresis appear promising, classic approaches are limited by substantial losses of plasma proteins and immune components. Photomodification of erythrocytes may enhance detoxification and stimulate tissue repair processes. Aim. To assess the clinical efficacy, safety, and impact on tissue repair of three variants of detoxifying hemocorrection: Therapeutic Plasma Exchange (TPE), TPE with Partial Photomodification of Erythrocytes (TPE-PPE), and Small Volume TPE with Full Photomodification of Erythrocytes (SV-TPE-FPE) in patients with acute pleural empyema. Materials and Methods. A total of 105 patients with acute nonspecific pleural empyema treated at the Institute of General and Emergency Surgery (2008–2024) were enrolled. Patients were stratified into four groups: control (standard therapy), TPE, TPE-PPE, and SV-TPE-FPE. Apheresis procedures were performed every other day. Efficacy was monitored via clinical parameters (body temperature, duration of fever, severity of condition), complications, and morphological changes. Statistical analysis was carried out using variation statistics and Student's t-test, with Bonferroni correction for multiple comparisons. The study was carried out as a private initiative of the authors, without grant support or state registration of the topic. Research Ethics. The study was conducted in accordance with the principles of the World Medical Association Declaration of Helsinki (1964–2024) and approved by the Ethics Committee of the Educational and Scientific Medical Institute of National Technical University "Kharkiv Polytechnic Institute" (Protocol No.2 dated October 13, 2023). Written informed consent for the use of clinical data in scientific research was obtained from all patients, with adherence to the principles of confidentiality and voluntary participation. Results. The SV-TPE-FPE group demonstrated the best clinical dynamics: maximal body temperature decreased to 37.1°C, and the fever period was shortest (mean ≈ 18 days). The complication rate in this group was significantly lower than in other groups: fewer purulent septic complications and a reduced need for surgical interventions. No deaths were recorded in the SV-TPE-FPE group. Morphologically, there was the largest proportion of spontaneous scarring of pleural cavities in this group, suggesting activation of reparative processes. Conclusions. Small volume TPE with full photomodification of erythrocytes (SV-TPE-FPE) appears to be a promising method for treating acute pleural empyema, combining effective detoxification with activation of repair and reduced complication rates with no fatal outcomes in the studied sample. These findings support incorporating photomodified erythrocytes into comprehensive therapy, but further multicenter randomized studies are required to validate these results. Keywords: surgery, purulent diseases of the pleura, laboratory diagnostic.

Open article ↗



proteins
2026-09-24 | Impact of urokinase shortage on empyema management and clinical outcomes in Japan.

Urokinase is an important fibrinolytic therapy for empyema. In February 2022, a nationwide shortage occurred, but its impact remains unclear. We conducted a retrospective cohort study using a nationwide Japanese administrative database. Adults with empyema who underwent pleural drainage or surgery from January 2020 to December 2023 were identified. Treatment changes were evaluated using interrupted time-series (ITS) analysis and visualized with an alluvial plot. Clinical outcomes were evaluated using multivariable logistic regression. The primary outcome was in-hospital mortality, and the secondary outcome was prolonged hospitalization (≥60 days). Among 9104 patients, urokinase use declined from 27.1% to 9.2%, whereas surgery increased from 18.9% to 23.0% after February 2022. ITS analysis demonstrated significant post-restriction slope changes in urokinase use (odds ratio [OR] = 0.87, 95% confidence interval [CI] = 0.86-0.88) and surgery (OR = 1.03, 95% CI = 1.01-1.04). The alluvial plot showed reduced urokinase use and increased surgical and conservative management. In-hospital mortality was 13.8% before and 14.5% after the shortage, and the shortage period was not associated with increased in-hospital mortality (adjusted OR: 1.05, 95% CI: 0.92-1.20). No clear increase in prolonged hospitalization was observed. The urokinase shortage substantially altered empyema management, although no clear worsening of short-term clinical outcomes was detected.

Open article ↗



2026-07-20 | Intrapleural Fibrinolytic Therapy in the Management of Pediatric Pleural Empyema: A Narrative Review

Background: Pediatric pleural empyema is a major complication of community-acquired pneumonia and remains associated with substantial morbidity despite advances in vaccination, antimicrobial therapy, and supportive care. Intrapleural fibrinolytic therapy has become an important minimally invasive treatment for complicated parapneumonic effusions and empyema, but uncertainty persists regarding the optimal fibrinolytic agent, treatment protocols, patient selection, and indications for surgical intervention. Methods: A narrative review of the literature was conducted to summarize current evidence on the use of intrapleural fibrinolytic therapy in pediatric pleural empyema. Experimental studies, randomized controlled trials, observational studies, systematic reviews, meta-analyses, and international clinical practice guidelines were critically reviewed. Particular attention was paid to the biological rationale for fibrinolysis, pharmacological characteristics of available agents, comparative effectiveness with video-assisted thoracoscopic surgery (VATS), practical treatment protocols, safety, and future research priorities. Results: Intrapleural fibrinolysis effectively improves pleural drainage by lysing fibrin septations during the fibrinopurulent stage of empyema and is associated with shorter hospitalization compared with chest-tube drainage alone. Urokinase remains the fibrinolytic agent supported by the highest-quality pediatric randomized evidence, whereas alteplase has demonstrated favorable outcomes in observational studies and randomized comparisons with VATS. Current evidence indicates comparable clinical outcomes between fibrinolysis and primary VATS in appropriately selected children, although fibrinolysis is generally associated with lower treatment costs and avoidance of surgery in most patients. Conventional-dose fibrinolytic therapy has an acceptable safety profile, with clinically significant bleeding reported only rarely. Current pediatric evidence does not support the routine addition of DNase to tissue plasminogen activator. Conclusion: Intrapleural fibrinolytic therapy represents a safe, effective, and minimally invasive first-line treatment for most children with complicated parapneumonic effusions and pleural empyema requiring drainage. Management should be individualized within a multidisciplinary framework, integrating timely diagnosis, image-guided pleural drainage, appropriate antimicrobial therapy, and selective surgical intervention. Future multicenter studies are needed to optimize fibrinolytic protocols, validate predictive biomarkers, and further standardize clinical management.

Open article ↗



2026-06-19 | Intrapleural Fibrinolytics use in Children with Pleural Empyema: Safe and Effective.

We assessed the number of children with pleural empyema in which video assisted thoracoscopy (VATS) could be avoided in a center where standard therapy is drainage using a chest drain with/without intrapleural fibrinolytics. We included all children referred for chest drainage of a pleural effusion to RadboudUMC between 01-2022 and 04-2023. Children were referred in case of pneumonia with respiratory distress and suspected pleural effusion on the chest X-ray or an effusion size >20mm in the chest ultrasound, indicating the need for chest drainage or VATS. We analyzed symptoms, test results, and treatment. Thirty-three children aged 0-16 years were referred for treatment of pleural effusion. Most children presented with fever, cough and dyspnea (72%). Four children presented with abdominal pain (13%), which led to 2 appendectomies prior to referral. In 11 (33%) children an invasive group A streptococcus was cultured from the pleural fluid. All patients were treated with antibiotics. One patient received VATS primarily. 27 (84%) patients received a chest drain and four patients continued conservative treatment. 14 (52%) of the 27 children with a chest drain were treated with intrapleural fibrinolytics (alteplase or urokinase) because of persistent pleural effusion on ultrasound despite chest drainage. No side effects were observed. Two patients received VATS secondary to chest drainage without receiving prior intrapleural fibrinolytics. Intrapleural fibrinolytic treatment appeared safe and could avoid VATS in children with poor drainage and is therefore a useful minimal invasive treatment in children with pleural empyema.

Open article ↗



2026-06-18 | The LTI-01-2001 phase 2a trial of intrapleural LTI-01 in patients with infected, non-draining pleural effusions.

Single chain urokinase (LTI-01) intrapleural enzymatic therapy (IET) was safe and promising in a phase 1 clinical trial to overcome failed drainage in patients with pleural infection. The LTI-01-2001 phase 2a trial was a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study in hospitalized subjects with infected, non-draining pleural effusions. LTI-01, in doses of 400,000, 800,000 or 1,200,000 Units, or placebo was administered intrapleurally once daily for up to 3 days. The primary efficacy endpoint was incidence of treatment failure within 7 days of starting study medication. Treatment failure was defined as requiring alternative pleural therapy irrespective of subsequent treatment. Pleural opacification was a secondary endpoint and was assessed by CT imaging of the change in opacified area expressed as a percentage of the ipsilateral hemithorax (relative change) or absolute change in pleural opacification volume expressed in liters. 40/43 enrolled patients received LTI-01 or placebo due to constraints of the COVID-19 pandemic. There was no significant difference in incidence of treatment failure between the LTI-01 and placebo groups (OR 1.04, 95% CI 0.24,4.44, P = 0.96) while two predetermined sensitivity analyses demonstrated trends of improved efficacy in the 400,000 U group (P = 0.052 and 0.147). The absolute (Liters; L) and relative change from baseline in opacity volume were - 0.28 L (p=0.035) and - 55.8% (P = 0.064) versus placebo in the 800,000 U group, with significant reduction in absolute opacification found in the 400,000 and all LTI-01-treated groups combined (P < 0.03, respectively). There were no safety signals of concern, nor were there any episodes of intrapleural or pulmonary bleeding in LTI-01-treated patients. No statistically significant difference in the incidence of treatment failure was seen, potentially related to low recruitment. Trends towards efficacy were observed in predetermined sensitivity analyses at the 400,000 U dose of intrapleural LTI-01. Pleural opacification appeared most improved by the 800,000 U intrapleural LTI-01. A larger phase 2b trial is required to confirm these results or determine the efficacy of LTI-01 in patients with organizing, nondraining, infected pleural effusions. ClinicalTrials.gov NCT04159831. Registration date: November 12, 2019.

Open article ↗



2026-05-25 | Extended Intrapleural Tissue Plasminogen Activator (tPA)-Dornase Alfa (DNase) Therapy Beyond the Standard Multicenter Intrapleural Sepsis Trial 2 (MIST-2) Regimen in a High-Risk Patient With Complex Empyema: A Case Report.

Pleural infection, including complicated parapneumonic effusion and empyema, remains a major management challenge, especially in patients who are poor surgical candidates. The Multicenter Intrapleural Sepsis Trial 2 (MIST-2) supports a six-dose regimen of intrapleural tissue plasminogen activator (tPA) plus dornase alfa (DNase), but the optimal duration of therapy in patients with persistent loculations remains uncertain. We describe a 62-year-old man with morbid obesity, New York Heart Association class III diastolic heart failure, and poorly controlled type 2 diabetes mellitus who presented with a complex, loculated left-sided empyema caused by Gemella sanguinis and Escherichia coli. Because of prohibitive operative risk, he was not considered a candidate for video-assisted thoracoscopic surgery. After incomplete improvement following the standard six-dose regimen, characterized by persistent fever, persistently elevated inflammatory markers, and residual loculations on repeat imaging, intrapleural therapy was extended for an additional six doses, for a total of 12 doses over six days. The patient had marked clinical and radiographic improvement, complete lung re-expansion, and no bleeding complications. This case suggests that, in carefully selected high-risk patients with persistent loculated empyema and no surgical option, extended intrapleural tPA-DNase therapy may be a feasible individualized strategy beyond the fixed MIST-2 protocol.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

2 orphan drug designations for Pleural empyema.

2 orphan drug designations for Pleural empyema.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

Single-chain urokinase plasminogen activator

proteins

EMA
2014-12-16

Phase II
Terminated

Scendea (NL) B.V.

single chain urokinase plasminogen activator

proteins

FDA
2014-09-11

Phase II
Terminated

Lung Therapeutics, Inc.

“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.